Biogen (BIIB) falls as earnings, revenue misses consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to Biogen (BIIB) falls as earnings, revenue misses consensus
February 13, 2024 7:00 AM EST
Biogen (NASDAQ: BIIB) reported Q4 EPS of $2.95, $0.23 worse than the analyst estimate of $3.18. Revenue for the quarter came in at $2.4 billion versus the consensus estimate of $2.47 billion.
GUIDANCE:
Biogen sees FY2024 EPS of $15.00-$16.00, versus the consensus of $15.64.
For earnings history and earnings-related data on Biogen (BIIB) click here.
...
More
February 12, 2024 4:06 PM EST
Biogen Inc. (Nasdaq: BIIB) announced the European Commission (EC) has authorized SKYCLARYS® (omaveloxolone) for the treatment of Friedreichs ataxia (FA) in adults and adolescents aged 16 years and older. SKYCLARYS is the first treatment approved within the European Union for this rare, genetic, progressive neurodegenerative disease.1
In my clinical practice, I have seen the devastating impact that Friedreichs ataxia has on patients and... More
February 9, 2024 10:00 AM EST
Aptar Digital Health, part of AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, has entered into an enterprise agreement with Biogen Inc. (Nasdaq: BIIB) to operate and develop digital health solutions for neurological and rare diseases. As part of the agreement, Biogen will transfer ownership of select digital health solutions to Aptar Digital Health (Aptar).
Through this collaboration, Aptar will provide a full range of capabilities including the product management, design, development and maintenance of... More
